CSIMarket
 
Mymd Pharmaceuticals Inc   (MYMD)
Other Ticker:  
 
 
Price: $2.4000 $-0.10 -4.000%
Day's High: $2.5 Week Perf: -6.61 %
Day's Low: $ 2.30 30 Day Perf: -32.01 %
Volume (M): 127 52 Wk High: $ 70.50
Volume (M$): $ 305 52 Wk Avg: $22.91
Open: $2.35 52 Wk Low: $2.11



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Mymd Pharmaceuticals Inc
Mymd Pharmaceuticals Inc is a pharmaceutical company that focuses on the development and commercialization of novel therapeutics. The company aims to address unmet medical needs and improve patient outcomes by utilizing innovative approaches in drug discovery and development. Mymd Pharmaceuticals Inc's research and development efforts include the identification and development of potential drug candidates to target various diseases and conditions. The company strives to bring safe and effective medicines to market that have the potential to revolutionize healthcare and improve the quality of life for patients.


   Company Address: 855 N. Wolfe Street Baltimore 21205 MD
   Company Phone Number: 848-8698   Stock Exchange / Ticker: NASDAQ MYMD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Mymd Pharmaceuticals Inc

Mymd Pharmaceuticals Inc's Troubling Third Quarter Earnings: A Bumpy Ride for Investors

During the past week, Mymd Pharmaceuticals Inc experienced a significant decline in its shares, dropping by -7.89%. This downward movement has further contributed to the company's already poor year-to-date performance, which now stands at -76.07%. Additionally, Mymd Pharmaceuticals Inc shares are currently trading only 7.6% above their 52-week low.
This decline in share value comes at a time when the In Vitro & In Vivo Diagnostic Substances industry is evaluating the third-quarter earnings of 2023. Specifically, MYMD, a key contributor to this industry, reported an operating loss of $-3.842588 million for the period between July and September 30, 2023. It is important to note that MYMD has not yet generated any revenue during this reporting season. However, market analysts anticipate additional revenue sources to emerge soon, given the current stage of the entity.

Mymd Pharmaceuticals Inc

Mymd Pharmaceuticals Inc Announces Operating Loss of $-5.781632 Million, Prompting Shareholders' Anticipation for Evolving Business Strategy

In recent developments within the In Vitro & In Vivo Diagnostic Substances industry, attention has been primarily focused on the performance of leading companies. However, there are some overlooked corporations that have released their financial numbers. One such corporation is MYMD, which announced an operating loss of $-5.781632 million for the second quarter of 2023.
Despite the disappointing financial performance, shareholders are eagerly waiting for MYMD's business strategy to evolve in the near future. They are placing less emphasis on the current operational results of the company, instead seeking a promising long-term plan. It is common for corporations to experience challenging periods as they strive to establish a robust business strategy. MYMD appears to have encountered one such period ending on June 30, 2023, as its deficit widened to $-4.168 million.

Mymd Pharmaceuticals Inc

MYMD Pharmaceuticals Inc. Shows Promising Growth in Q1 2023, Despite Operating Shortfall of $-2.59 Million

Investing in the stock market can be a lucrative way to grow your wealth, but it is important to proceed with caution and keep an eye on a company's financial performance. One recent development in the Biotechnology & Pharmaceuticals sector is the release of the first quarter 2023 earnings report by MYMD Pharmaceuticals Inc. While there are some positive signs, there are also reasons for caution.
One of the main concerns is the operating shortfall of $-2.590319 million, which is significant even though it represents an improvement from the first quarter of 2022. Investors should be aware that MYMD has not cited any revenue for the January to March 31 2023 reporting period, which could be cause for alarm. While the operating shortfall could be viewed as good news, it is important to note that this is exempt of easier comparisons and could change quickly.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com